logo
Plus   Neg
Share
Email

Nektar To Withdraw NDA For Oxycodegol

Nektar Therapeutics (NKTR) said that it has decided to withdraw the New Drug Application or NDA for oxycodegol and to make no further investment into the program. Earlier, the U.S. Food and Drug Administration' Committees did not recommend approval of oxycodegol.

The company estimates that this will afford its cost savings of between $75 million to $125 million in 2020 based upon its projections of the estimated costs related to commercialization plans and post-approval studies previously discussed with the FDA.

The company said it is disappointed in the Committees' vote regarding oxycodegol and believes it is also disappointing for patients suffering from chronic pain and the physicians that treat those patients who are currently relying on existing opioid therapies.

NKTR closed Tuesday trading at $27.96, up $0.56 or 2.04%. But, in the after-hours, the stock dropped $4.28 or 15.31 percent.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
J. M. Smucker Co. is recalling certain Natural Balance canned cat food, citing health concerns likely associated with increased levels of choline chloride, an animal growth promotant, the U.S. Food and Drug Administration said in a statement. The recall was initiated after receiving reports of adverse reactions. Polaris Industries Inc. is recalling certain Ranger and General Utility, as well as All-Terrain vehicles citing risks of crash, the U.S. Consumer Product Safety Commission said in a statement. The Medina, Minnesota-based company has called back about 26,730 units of Model Year 2019 - 2020 Ranger XP 1000 & Model Year 2020 General XP 1000 Utility vehicles. Gilead Sciences Inc. (GILD) said Friday that the European Commission has granted conditional marketing authorization for Veklury or remdesivir as a treatment for SARS-CoV-2 infection, the virus that causes COVID-19.
RELATED NEWS
Follow RTT